Stock comparison
Haemonetics
Smith & Nephew
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
SNN
Smith & Nephew
Market cap
$13.01B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | SNN | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 54C | HAE |
| Benjamin Graham | 85A | 68B | HAE |
| Philip Fisher | 60C | 45D | HAE |
| Peter Lynch | 54C | 57C | SNN |
| Joel Greenblatt | 31F | 33F | SNN |
| Charlie Munger | 54D | 47D | HAE |
| Terry Smith | 55D | 49D | HAE |
Side-by-side metrics
| Metric | HAE | SNN |
|---|---|---|
| Market cap | $2.98B | $13.01B |
| P/E (TTM) | 24.8x | 20.3x |
| EV/EBIT | 14.1x | 15.5x |
| ROIC (TTM) | 8.37% | 9.11% |
| Gross margin | 55.74% | 68.01% |
| Net margin | 7.29% | 10.14% |
| Revenue CAGR 5y | 7.65% | 4.34% |
| EPS CAGR 5y | 24.62% | 5.03% |
| Debt / Equity | 1.5x | 0.6x |
| Dividend yield | 0.0% | 2.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 5.03%+80%
- Revenue CAGR 5y7.65%vs 4.34%+43%
- EV/EBIT14.1xvs 15.5x+9%
SNN leads on
- Dividend yield2.62%vs 0.0%+100%
- Market cap$13.01Bvs $2.98B+77%
- Debt / Equity0.6xvs 1.5x+59%
- Net margin10.14%vs 7.29%+28%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.